Northwest Biotherapeutics (OTCMKTS:NWBO) versus Upstream Bio (NASDAQ:UPB) Financial Analysis

Upstream Bio (NASDAQ:UPB) and Northwest Biotherapeutics (OTCMKTS:NWBO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Risk and Volatility

Upstream Bio has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Northwest Biotherapeutics has a beta of -0.6, indicating that its stock price is 160% less volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of Northwest Biotherapeutics shares are held by institutional investors. 16.5% of Upstream Bio shares are held by insiders. Comparatively, 2.4% of Northwest Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Upstream Bio and Northwest Biotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85 million	137.98	-$143.44 million	($2.90)	-2.48
Northwest Biotherapeutics	$1.38 million	212.72	-$60.16 million	($18.23)	-0.01

Northwest Biotherapeutics has lower revenue, but higher earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Northwest Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Upstream Bio and Northwest Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Northwest Biotherapeutics	-1,736.35%	N/A	-56.34%

Analyst Recommendations

This is a breakdown of recent recommendations for Upstream Bio and Northwest Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1	2	4	0	2.43
Northwest Biotherapeutics	0	0	0	0	0.00

Upstream Bio presently has a consensus target price of $29.67, suggesting a potential upside of 313.18%. Given Upstream Bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe Upstream Bio is more favorable than Northwest Biotherapeutics.

Summary

Upstream Bio beats Northwest Biotherapeutics on 8 of the 14 factors compared between the two stocks.

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.